Intravenous Ferric Carboxymaltose (Ferinject®) With or Without Erythropoietin in Patients Undergoing Orthopaedic Surgery
Intravenous Ferric Carboxymaltose (Ferinject®) With or Without Erythropoietin for the Correction of Preoperative Anaemia in Patients Undergoing Orthopaedic Surgery
Sponsor: University of Zurich
Terminated
Not being able to recuit sufficient patients due to a lack of complience
Other terminated trials from University of Zurich
Other Iron Deficiency Anemia trials with similar outcome
Listed as NCT00706667, this PHASE4 trial focuses on Iron Deficiency Anemia and remains terminated or withdrawn. Sponsored by University of Zurich, it has been updated 7 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Oct 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Oct 2021 [monthly]
Terminated PHASE4
-
May 2020 — Jan 2021 [monthly]
Terminated PHASE4
▶ Show 2 earlier versions
-
Jun 2018 — May 2020 [monthly]
Terminated PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE4
First recorded
May 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Zurich
- Vifor Pharma
For direct contact, visit the study record on ClinicalTrials.gov .